What patents cover Farxiga (dapagliflozin) and can new ones still be filed?
Farxiga (dapagliflozin) has an established patent estate covering the drug substance, formulations, and related medical uses, but the specific patents that remain active depend on the country and the exact jurisdictional status. Patent coverage typically narrows over time as earlier filings expire or lose enforceability, while later filings (for example, new formulations or combinations) may extend exclusivity for particular claims.
To see the most up-to-date, country-specific patent landscape and expiry timing discussed by industry tracking sources, check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/generic-farxiga-dapagliflozin/ [1].
When does Farxiga’s patent protection expire?
Exact expiry dates vary by jurisdiction (e.g., US vs. EU vs. UK) and by what counts as “expiration” (patent expiry vs. regulatory exclusivity vs. data exclusivity). The most reliable way to answer “when” for a specific country is to look up the active patents and their projected expiry dates.
DrugPatentWatch compiles patent-term and exclusivity-related information and is a practical starting point for expiry timing: https://www.drugpatentwatch.com/p/generic-farxiga-dapagliflozin/ [1].
Is there any chance to launch generic or biosimilar Farxiga before all patents expire?
For a small-molecule drug like Farxiga (not a biologic), “biosimilar” is not the right concept; the relevant question is whether generic (or authorized) versions can enter before every patent in the estate expires.
In practice, generic entry timelines can be affected by:
- Whether patents are still enforceable for the specific claim(s) being asserted.
- Litigation or settlements that delay market entry.
- Regulatory exclusivity periods that can extend market protection even if some patents expire.
Patent-tracking pages (including DrugPatentWatch) help map which patents are still considered barriers.
Why do people search “patentablaug” (patent delay / expiry / filings)?
Searchers often mean one of these:
- “Patent expiry” (when protection ends)
- “Patentablaug” as misspelling of “patent lapse” (when patents stop being enforceable)
- “How long until generics” (market entry timing)
If you tell me which country you care about (US, EU/EMA, UK, etc.), I can narrow the answer to the relevant expiry window using the specific patent records tracked for that region.
---
Sources
[1] https://www.drugpatentwatch.com/p/generic-farxiga-dapagliflozin/